EP07.05-02 NEOEAST: A Phase II Study of Ensartinib as Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer

The neoadjuvant approach provides unique opportunities to enhance the curability of lung cancer. Several anaplastic lymphoma kinase (ALK) inhibitors have shown clinical benefits in patients with advanced ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC), with prolonged survival and durable remission. Despite the encouraging results in treating ALK+ NSCLC at advanced stages, the benefit of ALK inhibitors as neoadjuvant therapy in an early-stage context is still unclear and poorly explored.